Forty-nine-month survival in a metastatic renal cell carcinoma patient across six lines of targeted therapy
The survival and prognosis of mRCC patients may thus be significantly improved with the suitable use of newer targeted agents.02/26/2014
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Kidney Cancer | Renal Cell Carcinoma | Urology & Nephrology